All
Research
Education
Business
Solutions
EN
EN - English
CN - 中文
DE - Deutsch
ES - Español
KR - 한국어
IT - Italiano
FR - Français
PT - Português
TR - Türkçe
JA - 日本語
PL - Polski
RU - Русский
HE - עִברִית
AR - العربية
Sign In
Chapter 20
Pulmonary hypertension, or PH, denotes the resting mean pulmonary arterial pressure of 25 mm Hg or higher. Pulmonary hypertension can be classified into ...
Phosphodiesterase inhibitors treat pulmonary arterial hypertension or PAH by inhibiting the activity of the phosphodiesterase enzyme. Phosphodiesterase 5 ...
Endothelin receptor antagonists or ERAs counteract the effects of endothelins, or ETs, to treat pulmonary arterial hypertension or PAH. ETs are produced ...
Prostacyclin receptor agonists are vital in managing pulmonary arterial hypertension. They mimic prostaglandin I2 and bind to its receptor, IPR, on ...
Receptor tyrosine kinase inhibitors or TKIs and calcium channel blockers or CCBs are used for pulmonary arterial hypertension or PAH treatment. TKIs like ...
Oxygen therapy can enhance the quality of life of patients with pulmonary arterial hypertension or PAH who experience hypoxemia or low oxygen levels. This ...
Cystic fibrosis, or CF, is an autosomal recessive disorder resulting from mutations in the cystic fibrosis transmembrane conductance regulator or CFTR ...
Cystic fibrosis, or CF, is an autosomal genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator or CFTR gene. CF ...
Privacy
Terms of Use
Policies
Contact Us
Recommend to library
JoVE NEWSLETTERS
JoVE Journal
Methods Collections
JoVE Encyclopedia of Experiments
Archive
JoVE Core
JoVE Science Education
JoVE Lab Manual
JoVE Quiz
JoVE Playlist
Authors
Librarians
Access
ABOUT JoVE
JoVE Sitemap
Copyright © 2025 MyJoVE Corporation. All rights reserved